Fatemeh Chichagi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fatemeh Chichagi has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
Farzad Sheikhzadeh
School of Medicine, Iran University of Medical Sciences, Tehran, Iran
2 shared publications- Niloofar Deravi
Shahid Beheshti University of Medical Sciences
2 shared publications - Parisa Alsadat Dadkhah
School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
2 shared publications Abolfazl Qezelgachi
Student Research Committee, Qazvin University of Medical Sciences, Qazvin, Iran
1 shared publication- Akram Ansari
Medical College, Shantou University, Shantou, China
1 shared publication - Alaleh Alizadeh
Faculty of Medicine, Mashhad Branch Islamic Azad University Mashhad Iran
1 shared publication
Latest Publications
- 1 March 2025
- Published by Bentham Science Publishers Ltd. in Current Traditional Medicine
- Vol. 11 (2) , 1-15
The Antiviral Potential of Zingiber officinale (Ginger): A Comprehensive Literature Review
Herbal medicine has gained massive popularity among researchers worldwide. The leading causes of this rapid development are lower side effects, lower prices, and higher availability of plant extracts compared to synthetic drugs. Ginger (Zingiber officinale), from the Zingiberaceae family, is one of the most commonly used and popular plants utilized as a dietary spice, herbal medicine, and food preservative. Its biologically active components, such as shogaol, paradol, zingerone, and especially gingerol, can be highly effective for the treatment of several illnesses through various anti-inflammatory, anti-neoplastic, anti-emetic, anti-oxidant, antihyperlipidemic and anti-hyperglycaemic activities. Ginger can also be used as an antiviral agent. Numerous studies have been conducted to investigate the antiviral efficacy of ginger on several viruses; for instance, severe acute respiratory syndrome 2 (SARS-COV-2), influenza, dengue, hepatitis, herpes, Human Papilloma Virus (HPV), Human Immunodeficiency Virus (HIV), Epstein- Barr Virus (EBV), Chikungunya virus and so on. This review summarizes the efficacy of ginger in preventing or treating several viral diseases and its mechanism of action, emphasizing coronavirus disease 2019 (COVID-19) due to the current high burden of disease worldwide.
- 1 March 2025
- Published by Bentham Science Publishers Ltd. in Current Traditional Medicine
- Vol. 11 (2) , 1-15
The Antiviral Potential of Zingiber officinale (Ginger): A Comprehensive Literature Review
Herbal medicine has gained massive popularity among researchers worldwide. The leading causes of this rapid development are lower side effects, lower prices, and higher availability of plant extracts compared to synthetic drugs. Ginger (Zingiber officinale), from the Zingiberaceae family, is one of the most commonly used and popular plants utilized as a dietary spice, herbal medicine, and food preservative. Its biologically active components, such as shogaol, paradol, zingerone, and especially gingerol, can be highly effective for the treatment of several illnesses through various anti-inflammatory, anti-neoplastic, anti-emetic, anti-oxidant, antihyperlipidemic and anti-hyperglycaemic activities. Ginger can also be used as an antiviral agent. Numerous studies have been conducted to investigate the antiviral efficacy of ginger on several viruses; for instance, severe acute respiratory syndrome 2 (SARS-COV-2), influenza, dengue, hepatitis, herpes, Human Papilloma Virus (HPV), Human Immunodeficiency Virus (HIV), Epstein- Barr Virus (EBV), Chikungunya virus and so on. This review summarizes the efficacy of ginger in preventing or treating several viral diseases and its mechanism of action, emphasizing coronavirus disease 2019 (COVID-19) due to the current high burden of disease worldwide.
- 27 September 2024
- Published by Wolters Kluwer Health in Topics in Clinical Nutrition
- Vol. 39 (4) , 277-287
The Association Between Baseline Vitamin D Level and Clinical Outcomes in Patients With COVID-19
Our study aimed to understand the link between baseline vitamin D levels at admission and in-hospital clinical outcome and 7-month all-cause mortality in patients hospitalized with COVID-19. Sixty-three percent of 636 Iranian patients had insufficient 25(OH)vitamin D baseline levels (P = .022), 7-month all-cause mortality (P = .047), and multiple-organ damage (P = .035) in patients with COVID-19. No association between other in-hospital complications and 25(OH)vitamin D levels was found.
- 27 September 2024
- Published by Wolters Kluwer Health in Topics in Clinical Nutrition
- Vol. 39 (4) , 277-287
The Association Between Baseline Vitamin D Level and Clinical Outcomes in Patients With COVID-19
Our study aimed to understand the link between baseline vitamin D levels at admission and in-hospital clinical outcome and 7-month all-cause mortality in patients hospitalized with COVID-19. Sixty-three percent of 636 Iranian patients had insufficient 25(OH)vitamin D baseline levels (P = .022), 7-month all-cause mortality (P = .047), and multiple-organ damage (P = .035) in patients with COVID-19. No association between other in-hospital complications and 25(OH)vitamin D levels was found.
- Open Access
- 28 November 2023
- Published by SAGE Publications in Diabetes & Vascular Disease Research
- Vol. 20 (6)
Lipoprotein (a) as a predictor of diabetic retinopathy in patients with type 2 diabetes: A systematic review
Background: Lipoprotein a (LP(a)), an LDL-like lipoprotein, known as a risk factor for cardiovascular diseases, has a controversial association with diabetic retinopathy in patients with type 2 diabetes—the current systematic review aimed to critically assess the association between LP(a) and diabetic retinopathy. Methods: A systematic review of relevant studies was conducted after a thorough search in PubMed, Scopus, and Google Scholar electronic databases. We used English observational, case-control, and prospective cohort studies published up to August 2022, including type 2 diabetic patients as the population, diabetic retinopathy as the outcome, and LP(a) as the intervention. Result: 17 relevant studies, including 4688 patients with diabetes, were included in this systematic review. While in 13 studies, Lipoprotein(a) was recognized as a risk factor for diabetic retinopathy, only three studies reported no evidence of a relationship between the two. Also, another study showed a mixed outcome of the relationship between LP(a) and diabetic retinopathy. Conclusion: High serum lipoprotein(a) in patients with type 2 diabetes is considered a risk factor for diabetic retinopathy. However, further large-scaled cohort studies are still required to validate this finding.
- 28 November 2023
- Published by SAGE Publications in Diabetes & Vascular Disease Research
- Vol. 20 (6)
Open AccessLipoprotein (a) as a predictor of diabetic retinopathy in patients with type 2 diabetes: A systematic review
Background: Lipoprotein a (LP(a)), an LDL-like lipoprotein, known as a risk factor for cardiovascular diseases, has a controversial association with diabetic retinopathy in patients with type 2 diabetes—the current systematic review aimed to critically assess the association between LP(a) and diabetic retinopathy. Methods: A systematic review of relevant studies was conducted after a thorough search in PubMed, Scopus, and Google Scholar electronic databases. We used English observational, case-control, and prospective cohort studies published up to August 2022, including type 2 diabetic patients as the population, diabetic retinopathy as the outcome, and LP(a) as the intervention. Result: 17 relevant studies, including 4688 patients with diabetes, were included in this systematic review. While in 13 studies, Lipoprotein(a) was recognized as a risk factor for diabetic retinopathy, only three studies reported no evidence of a relationship between the two. Also, another study showed a mixed outcome of the relationship between LP(a) and diabetic retinopathy. Conclusion: High serum lipoprotein(a) in patients with type 2 diabetes is considered a risk factor for diabetic retinopathy. However, further large-scaled cohort studies are still required to validate this finding.
- 20 November 2023
- Published by Taylor & Francis in Journal of Addictive Diseases
- Vol. 42 (4) , 313-325
Cardiovascular health in kratom users; a narrative review
Kratom, also known as Mitragyna speciosa, is a plant that originates in Southeast Asia and possesses unique pharmacological characteristics. It is commonly consumed in the form of tea made by boiling the leaves or using the leaves to create the powder. According to its pain-relieving effects, the prevalence of kratom use around the world has increased, which has various implications for healthcare providers. Mitragynine is a well-known active compound in kratom. This review aims to provide a comprehensive perspective on the cardiovascular effects of mitragynine and its potential cardiotoxicity through the literature. Authors searched PubMed, Scopus, and Google Scholar databases using appropriate search strategies for each database. After the screening, all relevant studies were included. Although kratom may have the potential for therapeutic benefits, it has been associated with multi-organ damage and cardiac toxicity in some cases. According to the available data, tachycardia and hypertension are the most common adverse effects. Other possible cardiovascular effects include atherosclerosis, ventricular arrhythmia, cardiomyopathy, dose-dependent prolonged QTc interval, myocarditis, cardiomegaly, and cardiopulmonary arrest. While prior research has indicated the possible negative effects of mitragynine overdose on the cardiovascular system, there are no definitive conclusions, and additional investigations are needed.
- 20 November 2023
- Published by Taylor & Francis in Journal of Addictive Diseases
- Vol. 42 (4) , 313-325
Cardiovascular health in kratom users; a narrative review
Kratom, also known as Mitragyna speciosa, is a plant that originates in Southeast Asia and possesses unique pharmacological characteristics. It is commonly consumed in the form of tea made by boiling the leaves or using the leaves to create the powder. According to its pain-relieving effects, the prevalence of kratom use around the world has increased, which has various implications for healthcare providers. Mitragynine is a well-known active compound in kratom. This review aims to provide a comprehensive perspective on the cardiovascular effects of mitragynine and its potential cardiotoxicity through the literature. Authors searched PubMed, Scopus, and Google Scholar databases using appropriate search strategies for each database. After the screening, all relevant studies were included. Although kratom may have the potential for therapeutic benefits, it has been associated with multi-organ damage and cardiac toxicity in some cases. According to the available data, tachycardia and hypertension are the most common adverse effects. Other possible cardiovascular effects include atherosclerosis, ventricular arrhythmia, cardiomyopathy, dose-dependent prolonged QTc interval, myocarditis, cardiomegaly, and cardiopulmonary arrest. While prior research has indicated the possible negative effects of mitragynine overdose on the cardiovascular system, there are no definitive conclusions, and additional investigations are needed.